Small molecules for inhibiting male fertility

US10472334B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10472334-B2
Application numberUS-201515122528-A
CountryUS
Kind codeB2
Filing dateMar 13, 2015
Priority dateMar 14, 2014
Publication dateNov 12, 2019
Grant dateNov 12, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic the binding of anti-EPPIN antibodies to EPPIN, and thus inhibit the forward motility of sperm in humans and other primates. In another embodiment, the compounds described herein inhibit or enhance EPPIN-semenogelin binding, and inhibit forward motility of sperm. The assays described herein identify compounds which inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant EPPIN and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of providing contraception, comprising administering an effective amount of a compound having one of the following formulas: and tautomers, and pharmaceutically-acceptable salts thereof, wherein: R 1 is —CH 2 R 5 , R 2 is H, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, alkylaryl, C(X)R 6 or C(X)XR 6 , R 3 is —NHR 7 , —C(X)NHR 7 , —NHC(X)R 7 , —NHC(X)XR 7 , —R 8 , or C(X)R 8 ; R 4 is OR 7 or —C(X)OR 7 , R 5 is H, F, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, alkylaryl, —XC(X)XR 6 , C(X)XR 6 , or C(X)R 6 , R 6 and R 7 are H, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, or alkylaryl; R 8 is X is O, S, or NR 7 , Y is O, S, NR 7 , or C(R 7 ) 2 , Zj refers to j number of Z substituents, which substituents can be present at any carbon atom on the benzene ring, wherein j is 0, 1 or 2, each Z is, individually, a substituent species selected from the group consisting of C 1-8 alkyl, C 1-8 substituted alkyl, C 2-8 alkenyl, C 2-8 substituted alkenyl, C 3-8 cycloalkyl, C 3-8 substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, halo, —OR 7 , —N(R 7 ) 2 , —CF 3 , —CN, —NO 2 , —C 2 R 7 , —SR 7 , —N 3 , —C(═O)N(R 7 ) 2 , —NR 7 C(═O)R 7 , —C(═O)R 7 , —C(═O)OR 7 , —OC(═O)R 7 , —O(CR 6 R 7 ) r C(═O)R 7 —, —O(CR 6 R 7 ) r NR 7 C(═O)R 7 , —O(CR 6 R 7 ) r NR 7 SO 2 R 7 , —OC(═O)NR 6 R 7 , —NR 7 C(═O)OR 7 , —SO 2 R 7 , —SO 2 NR 6 R 7 , and —NR 7 SO 2 R 7 , r is an integer from 1 to 6, and n is 0, 1, 2, or 3, the term “substituted” as applied to alkyl, aryl, cycloalkyl and the like refers to the substituents described above, starting with halo and ending with —NR 7 SO 2 R 7 ; and tautomers, and pharmaceutically-acceptable salts thereof, wherein the compounds can exist as single stereoisomers or as mixtures of stereoisomers. 2. The method of claim 1 , wherein haloalkyl is mono-fluoromethyl. 3. The method of claim 1 , wherein R 5 is F, —XC(X)XR—, or C(X)XR 6 . 4. The method of claim 1 , wherein one or more C═X moieties are carbonyl (C═O). 5. A method of providing contraception, comprising an effective amount of a compound having one of the following formulas: 6. A pharmaceutical composition for providing male contraception, comprising an effective amount of a compound of claim 1 . 7. The composition of claim 6 , further comprising a water-soluble lubricant. 8. A compound having one of the following formulas: and tautomers, and pharmaceutically-acceptable salts thereof, wherein: R 1 is —CH 2 R 5 , R 2 is H, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, alkylaryl, C(X)R 6 or C(X)XR 6 , R 3 is —NHR 7 , —C(X)NHR 7 , —NHC(X)R 7 , —NHC(X)XR 7 , —R 8 , or C(X)R 8 ; R 4 is OR′ or —C(X)OR 7 , R 5 is H, F, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, alkylaryl, —XC(X)XR 6 , C(X)XR 6 , or C(X)R 6 , R 6 and R 7 are H, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, or alkylaryl; R 8 is X is O, S, or NR 7 , Y is O, S, NR′, or C(R 7 ) 2 , Zj refers to j number of Z substituents, which substituents can be present at any carbon atom on the benzene ring, wherein j is 0, 1 or 2, each Z is, individually, a substituent species selected from the group consisting of C 1-8 alkyl, C 1-8 substituted alkyl, C 2-8 alkenyl, aryl, alkylaryl, arylalkyl, halo, —OR 7 , —N(R 7 ) 2 , —CF 3 , —CN, —NO 2 , —C 2 R 7 , —SR 7 , —N 3 , —C(═O)N(R 7 ) 2 , —NR 7 C(═O)R 7 , —C(═O)R 7 , —C(═O)OR 7 , —OC(═O)R 7 , —O(CR 6 R 7 ) r C(═O)R 7 —, —O(CR 6 R 7 ) r NR 7 C(═O)R 7 , —O(CR 6 R 7 ) r NR 7 SO 2 R 7 , —OC(═O)NR 6 R 7 , —NR 7 C(═O)OR 7 , —SO 2 R 7 , —SO 2 NR 6 R 7 , and —NR 7 SO 2 R 7 , r is an integer from 1 to 6, and n is 0, 1, 2, or 3, and tautomers, and pharmaceutically-acceptable salts thereof, wherein the compounds can exist as single stereoisomers or as mixtures of stereoisomers. 9. The compound of claim 8 , wherein haloalkyl is mono-fluoromethyl. 10. The compound of claim 8 , wherein R 5 is F, —XC(X)XR 6 , or C(X)XR 6 . 11. The compound of claim 8 , wherein one or more C═X moieties are carbonyl (C═O). 12. A compound of claim 8 , wherein the compound has the formula: or a pharmaceutically acceptable salt, or tautomer thereof. 13. A compound of claim 8 , having one of the following formulas: or a pharmaceutically acceptable salt, or tautomer thereof. 14. A compound of claim 8 , having the formula: or a pharmaceutically acceptable salt, or tautomer thereof.

Assignees

Inventors

Classifications

  • Masculine contraceptives · CPC title

  • Two hetero atoms, in positions 3 and 5 · CPC title

  • with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title

  • having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title

  • Ortho-condensed systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10472334B2 cover?
Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic the binding of anti-EPPIN antibodies to EPPIN, and thus inhibit the forward motility of sperm in humans and other primates. In another embodiment, the compound…
Who is the assignee on this patent?
Univ North Carolina Chapel Hill
What technology area does this patent fall under?
Primary CPC classification C07D251/52. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).